All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail

DBV to make new approval bid for VIASKIN Peanut on Phase III trial

DBV Technologies will be making another attempt at gaining US Food and Drug Administration (FDA) approval for its peanut allergy…
Aviceda Therapeutics to advance eye disease drug despite Phase IIb loss

Aviceda Therapeutics’ eye disease drug will advance to Phase III, despite it failing to meet the primary endpoint in a…
Gilead’s HIV ART combo deemed non-inferior in second Phase III trial

Gilead Sciences’ human immunodeficiency virus (HIV) single-tablet combination antiretroviral therapy (ART) has proven non-inferior to standard of care (SoC) in a…
Rezolute stock crashes after sole pipeline candidate fails Phase III

Rezolute’s stock has crashed after its only pipeline product flopped in a Phase III trial. In the sunRIZE trial (NCT06208215),…
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial

Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4…

AI takes charge of data, but challenges linger

For years, one of the biggest barriers to effectively implementing artificial intelligence (AI) into clinical trial data management has been…
APAC’s rising stars beyond China

While China continues to dominate clinical trial activity across Asia-Pacific (APAC) and globally, other countries are rapidly emerging as significant…
Roche posts second Phase III win for oral SERD

Roche’s oral selective oestrogen receptor degrader (SERD) has reduced the risk of invasive disease recurrence or death by 30% in…
Dyne to seek accelerated approval of DMD drug on Phase I/II data

Dyne Therapeutics is seeking US accelerated approval of its Duchenne muscular dystrophy (DMD) drug after it met its endpoints in…
Kallyope’s migraine drug advances to pivotal trial

Kallyope is advancing its lead migraine drug to pivotal trials after it has shown to be competitive with marketed therapies…